Galkin V V, Malev I V, Dovgan' E V, Kozlov S N, Rafal'skiĭ V V
Urologiia. 2011 Jan-Feb(1):13-6.
A prospective multicenter randomized trial enrolled 104 females aged 18-55 years with acute un-complicated cystitis. The patients were randomized into two groups: 49 patients of group 1 received cefixim in a single dose 400 mg/day for 5 days; 55 patients of group 2 were given ciprofloxacin in a dose 250-500 mg twice a day for 5 days. Clinical and microbiological assessment of efficacy and safety was made before treatment and on treatment day 8 and 28. Significant differences were found between groups 1 and 2 in parameters of bacteriological and clinical efficacy. Eradication of the agent and persistent bacteriological response was seen in 95.9 and 100% patients of group 1, 66 and 100% patients of group 2, respectively. Complete and partial response was observed in 55.1 and 75.5% patients of group 1, 37.3 and 58.1% patients of group 2, respectively. Thus, cefixim in a single dose 400 mg/day for 5 days has a higher microbiological efficacy than ciprofloxacin in a dose 250-500 mg twice a day. Side effects occurred less frequently in the treatment with cefixim.
一项前瞻性多中心随机试验纳入了104名年龄在18至55岁之间的患有急性单纯性膀胱炎的女性。患者被随机分为两组：第1组的49名患者接受单剂量400毫克/天的头孢克肟治疗，持续5天；第2组的55名患者给予环丙沙星，剂量为250 - 500毫克，每日两次，持续5天。在治疗前以及治疗第8天和第28天对疗效和安全性进行了临床和微生物学评估。第1组和第2组在细菌学和临床疗效参数方面存在显著差异。第1组分别有95.9%和100%的患者病原体被根除且细菌学反应持续存在，第2组分别为66%和100%。第1组分别有55.1%和75.5%的患者出现完全和部分反应，第2组分别为37.3%和58.1%。因此，单剂量400毫克/天的头孢克肟持续5天的微生物学疗效高于每日两次250 - 500毫克剂量的环丙沙星。头孢克肟治疗中的副作用发生频率较低。
